Biofunctionalized magnetic nanoparticles for specifically detecting biomarkers of Alzheimer's disease in vitro

Che Chuan Yang, Shieh Yueh Yang, Jen Jie Chieh, Herng Er Horng, Chin Yih Hong, Hong Chang Yang, K. H. Chen, B. Y. Shih, Ta Fu Chen, Ming Jang Chiu

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Magnetic nanoparticles biofunctionalized with antibodies against β-amyloid-40 (Aβ-40) and Aβ-42, which are promising biomarkers related to Alzheimer's disease (AD), were synthesized. We characterized the size distribution, saturated magnetizations, and stability of the magnetic nanoparticles conjugated with anti-Aβ antibody. In combination with immunomagnetic reduction technology, it is demonstrated such biofunctionalized magnetic nanoparticles are able to label Aβs specifically. The ultralow-detection limits of assaying Aβs in vitro using the magnetic nanoparticles via immunomagnetic reduction are determined to a concentration of ~10 ppt (10 pg/mL). Further, immunomagnetic reduction signals of Aβ-40 and Aβ-42 in human plasma from normal samples and AD patients were analyzed, and the results showed a significant difference between these two groups. These results show the feasibility of using magnetic nanoparticles with Aβs as reagents for assaying low-concentration Aβs through immunomagnetic reduction, and also provide a promising new method for early diagnosis of Alzheimer's disease from human blood plasma.

Original languageEnglish
Pages (from-to)500-505
Number of pages6
JournalACS Chemical Neuroscience
Volume2
Issue number9
DOIs
Publication statusPublished - 2011 May 30

Fingerprint

Biomarkers
Nanoparticles
Alzheimer Disease
Plasma (human)
Antibodies
Amyloid
Limit of Detection
Labels
Early Diagnosis
Anti-Idiotypic Antibodies
Magnetization
Blood
In Vitro Techniques
Technology
Plasmas

Keywords

  • Immunomagnetic reduction
  • Magnetic nanoparticles
  • β-amyloid

ASJC Scopus subject areas

  • Biochemistry
  • Physiology
  • Cognitive Neuroscience
  • Cell Biology

Cite this

Biofunctionalized magnetic nanoparticles for specifically detecting biomarkers of Alzheimer's disease in vitro. / Yang, Che Chuan; Yang, Shieh Yueh; Chieh, Jen Jie; Horng, Herng Er; Hong, Chin Yih; Yang, Hong Chang; Chen, K. H.; Shih, B. Y.; Chen, Ta Fu; Chiu, Ming Jang.

In: ACS Chemical Neuroscience, Vol. 2, No. 9, 30.05.2011, p. 500-505.

Research output: Contribution to journalArticle

Yang, Che Chuan ; Yang, Shieh Yueh ; Chieh, Jen Jie ; Horng, Herng Er ; Hong, Chin Yih ; Yang, Hong Chang ; Chen, K. H. ; Shih, B. Y. ; Chen, Ta Fu ; Chiu, Ming Jang. / Biofunctionalized magnetic nanoparticles for specifically detecting biomarkers of Alzheimer's disease in vitro. In: ACS Chemical Neuroscience. 2011 ; Vol. 2, No. 9. pp. 500-505.
@article{91443b900ca94839b663e20225de86f5,
title = "Biofunctionalized magnetic nanoparticles for specifically detecting biomarkers of Alzheimer's disease in vitro",
abstract = "Magnetic nanoparticles biofunctionalized with antibodies against β-amyloid-40 (Aβ-40) and Aβ-42, which are promising biomarkers related to Alzheimer's disease (AD), were synthesized. We characterized the size distribution, saturated magnetizations, and stability of the magnetic nanoparticles conjugated with anti-Aβ antibody. In combination with immunomagnetic reduction technology, it is demonstrated such biofunctionalized magnetic nanoparticles are able to label Aβs specifically. The ultralow-detection limits of assaying Aβs in vitro using the magnetic nanoparticles via immunomagnetic reduction are determined to a concentration of ~10 ppt (10 pg/mL). Further, immunomagnetic reduction signals of Aβ-40 and Aβ-42 in human plasma from normal samples and AD patients were analyzed, and the results showed a significant difference between these two groups. These results show the feasibility of using magnetic nanoparticles with Aβs as reagents for assaying low-concentration Aβs through immunomagnetic reduction, and also provide a promising new method for early diagnosis of Alzheimer's disease from human blood plasma.",
keywords = "Immunomagnetic reduction, Magnetic nanoparticles, β-amyloid",
author = "Yang, {Che Chuan} and Yang, {Shieh Yueh} and Chieh, {Jen Jie} and Horng, {Herng Er} and Hong, {Chin Yih} and Yang, {Hong Chang} and Chen, {K. H.} and Shih, {B. Y.} and Chen, {Ta Fu} and Chiu, {Ming Jang}",
year = "2011",
month = "5",
day = "30",
doi = "10.1021/cn200028j",
language = "English",
volume = "2",
pages = "500--505",
journal = "ACS Chemical Neuroscience",
issn = "1948-7193",
publisher = "American Chemical Society",
number = "9",

}

TY - JOUR

T1 - Biofunctionalized magnetic nanoparticles for specifically detecting biomarkers of Alzheimer's disease in vitro

AU - Yang, Che Chuan

AU - Yang, Shieh Yueh

AU - Chieh, Jen Jie

AU - Horng, Herng Er

AU - Hong, Chin Yih

AU - Yang, Hong Chang

AU - Chen, K. H.

AU - Shih, B. Y.

AU - Chen, Ta Fu

AU - Chiu, Ming Jang

PY - 2011/5/30

Y1 - 2011/5/30

N2 - Magnetic nanoparticles biofunctionalized with antibodies against β-amyloid-40 (Aβ-40) and Aβ-42, which are promising biomarkers related to Alzheimer's disease (AD), were synthesized. We characterized the size distribution, saturated magnetizations, and stability of the magnetic nanoparticles conjugated with anti-Aβ antibody. In combination with immunomagnetic reduction technology, it is demonstrated such biofunctionalized magnetic nanoparticles are able to label Aβs specifically. The ultralow-detection limits of assaying Aβs in vitro using the magnetic nanoparticles via immunomagnetic reduction are determined to a concentration of ~10 ppt (10 pg/mL). Further, immunomagnetic reduction signals of Aβ-40 and Aβ-42 in human plasma from normal samples and AD patients were analyzed, and the results showed a significant difference between these two groups. These results show the feasibility of using magnetic nanoparticles with Aβs as reagents for assaying low-concentration Aβs through immunomagnetic reduction, and also provide a promising new method for early diagnosis of Alzheimer's disease from human blood plasma.

AB - Magnetic nanoparticles biofunctionalized with antibodies against β-amyloid-40 (Aβ-40) and Aβ-42, which are promising biomarkers related to Alzheimer's disease (AD), were synthesized. We characterized the size distribution, saturated magnetizations, and stability of the magnetic nanoparticles conjugated with anti-Aβ antibody. In combination with immunomagnetic reduction technology, it is demonstrated such biofunctionalized magnetic nanoparticles are able to label Aβs specifically. The ultralow-detection limits of assaying Aβs in vitro using the magnetic nanoparticles via immunomagnetic reduction are determined to a concentration of ~10 ppt (10 pg/mL). Further, immunomagnetic reduction signals of Aβ-40 and Aβ-42 in human plasma from normal samples and AD patients were analyzed, and the results showed a significant difference between these two groups. These results show the feasibility of using magnetic nanoparticles with Aβs as reagents for assaying low-concentration Aβs through immunomagnetic reduction, and also provide a promising new method for early diagnosis of Alzheimer's disease from human blood plasma.

KW - Immunomagnetic reduction

KW - Magnetic nanoparticles

KW - β-amyloid

UR - http://www.scopus.com/inward/record.url?scp=84865491507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865491507&partnerID=8YFLogxK

U2 - 10.1021/cn200028j

DO - 10.1021/cn200028j

M3 - Article

C2 - 22860173

AN - SCOPUS:84865491507

VL - 2

SP - 500

EP - 505

JO - ACS Chemical Neuroscience

JF - ACS Chemical Neuroscience

SN - 1948-7193

IS - 9

ER -